Life Sciences

Illinois biomedical company AbbVie, which has facilities in Worcester, announced on Tuesday a $30-million collaborative research alliance with Harvard Medical School in Boston to study and develop novel therapies against emergent viral infections. 

Biotechnology startup Enrich Therapeutics, based in Worcester and Groton, Conn., has received a $1.7-million grant from the National Institute of Allergy and Infectious Diseases.

The coronavirus pandemic is boosting the life science industry in Greater Boston, including suburban areas sometimes left in the long shadows of hubs like Kendall Square.

This year’s 40 Under Forty class is certainly like no other. Although full of the archetypal up-and-coming leaders of Central Massachusetts business organizations, each member of the Class of 2020 has found a way to thrive in the midst of an international crisis.

StageBio, a company with locations in Virginia and Maryland, has expanded into the Massachusetts market with a new, 10-person facility in Marlborough.

Galaxy Life Sciences, a sister company to the developer of the Trolley Yard retail complex in Worcester, on Friday evening announced plans to spend at least $50 million to develop a biomanufacturing facility at the 46-acre Worcester life sciences campus The Reactory.

Massachusetts is among seven states that are entering formal talks with manufacturers with the goal of facilitating rapid point-of-care antigen tests that could more quickly detect COVID-19 outbreaks in workplaces, schools and congregate care settings.

Medical technology company Hologic, headquartered in Marlborough, announced on Monday it is launching a campaign in conjunction with nine-time Grammy winner Sheryl Crow to encourage people to schedule mammograms that were delayed due to the coronavirus pandemic.

Akoya Biosciences, a Marlborough firm analyzing tissues for therapy research, has signed a collaboration with the Helen Diller Family Comprehensive Cancer Center at the University of California San Francisco.

Just over a month before the first switches out its CEO, Milford life sciences company Waters Corp. on Tuesday announced its profits dropped 15% in the second quarter, as its revenues fell 13%.